-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 20212021-06-02
-
VOLUNTARY ANNOUNCEMENT - RESULTS OF THE PHASE III AENEAS STUDY OF AMEILE AS THE FIRST-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER WILL BE PUBLISHED AT THE 2021 ASCO ANNUAL MEETING2021-05-20
-
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF AMEILE IN FIRST LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2021-05-13
-
VOLUNTARY ANNOUNCEMENT - FDA TENTATIVE APPROVAL OF“BORTEZOMIB FOR INJECTION”2021-05-10
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 20212021-05-07
-
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 3, 20212021-04-27
-
NOTICE OF ANNUAL GENERAL MEETING2021-04-27
-
PROPOSED RE-ELECTION OF DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING2021-04-27
-
Next Day Disclosure Return2021-04-19
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 20212021-04-07
-
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF“LENALIDOMIDE CAPSULE”2021-04-01
-
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 20202021-03-30
